KA

KINETA INC
NASDAQ
0.4680
-0.0078
-1.63%
After Hours: 0.4511 -0.0169 -3.61% 16:47 05/23 EDT
OPEN
0.4758
PREV CLOSE
0.4758
HIGH
0.4758
LOW
0.4400
VOLUME
30.19K
TURNOVER
0
52 WEEK HIGH
5.39
52 WEEK LOW
0.3339
MARKET CAP
5.74M
P/E (TTM)
-0.3011
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KA last week (0513-0517)?
Weekly Report · 3d ago
Kinetta, Inc. Quarterly Report on Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/16 07:43
KA Stock Earnings: Kineta Misses EPS for Q1 2024
Kineta reported earnings per share of -89 cents for the first quarter of 2024. The company did not report any revenue for the quarter. Kineta's earnings were below the analyst estimate for EPS of -21 cents. Kineta is a company that has been around since the 1970s.
Investorplace · 05/16 01:54
Kineta GAAP EPS of -$0.89
Seeking Alpha · 05/15 21:06
Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor
Benzinga · 05/15 20:21
Kineta Q1 EPS $(0.89) Misses $(0.21) Estimate
Benzinga · 05/15 20:20
*Kineta 1Q Loss/Shr 89c >KA
Dow Jones · 05/15 20:03
KINETA INC Q1 EPS $-0.89
Reuters · 05/15 20:01
More
About KA
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Webull offers Kineta Inc stock information, including NASDAQ: KA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KA stock methods without spending real money on the virtual paper trading platform.